scholarly journals Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis

2018 ◽  
Vol 18 (2) ◽  
pp. 126-139 ◽  
Author(s):  
Aaron Dane ◽  
Amy Spencer ◽  
Gerd Rosenkranz ◽  
Ilya Lipkovich ◽  
Tom Parke ◽  
...  
2019 ◽  
Vol 59 ◽  
pp. 229-231 ◽  
Author(s):  
Aaron E. Miller ◽  
Xianhao Xu ◽  
Richard Macdonell ◽  
Steve Vucic ◽  
Philippe Truffinet ◽  
...  

Haematologica ◽  
2021 ◽  
Author(s):  
Marcelo Capra ◽  
Thomas Martin ◽  
Philippe Moreau ◽  
Ross Baker ◽  
Ludek Pour ◽  
...  

Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The Phase 3 IKEMA study (NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) vs Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate


2010 ◽  
Vol 2 (4) ◽  
pp. 435-454 ◽  
Author(s):  
José Pinheiro ◽  
Frederic Sax ◽  
Zoran Antonijevic ◽  
Björn Bornkamp ◽  
Frank Bretz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document